AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada

RegulatoryAMO-02Positive

AI Analysis

Summary

AMO Pharma announced receipt of scientific advice from the FDA, MHRA, and Health Canada regarding the design of a registrational clinical study for AMO-02 in Congenital Myotonic Dystrophy Type 1, with hospitalization as the primary outcome measure supported by functional assessments.

Clinical Trial Data

Phase

registrational

Outcome Details

Scientific advice received from FDA, MHRA, and Health Canada; registrational study design incorporates hospitalization as primary outcome with functional assessments as secondary outcomes

Importance:6/10

Sentiment:

0.60

rare diseaseregulatory guidancecongenital myotonic dystrophyclinical trial designFDA interaction

Related Companies

$HR $MEHA $HIT

Read the original article

Published by PR Newswire Biotech on July 6, 2026 9:49 PM

Read Original